hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma [Hematologic Malignancy]

AbstractPurpose We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuselarge B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients ... [Published Journal of Clinical Oncology - 5 hours ago]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Anchors Away

October 2014 , Volume 29 , Issue 10 , pp 1414-1418Date:20 May 2014Rent the article at a discountRent now* Final gross prices may vary according to local VAT.Get AccessThis is an excerpt from the contentIn this series, a clinician extemporaneously discusses ... [Published Springer Link Journal - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide [Hematologic Malignancy]

PurposeArsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). QT interval prolongation is common with ATO and can pose a barrier to effective administration. The objective of this study was to characterize ... [Published Journal of Clinical Oncology - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial [Hematologic Malignancy]

PurposeThe introduction of all- trans -retinoic acid (ATRA) has significantly improved outcomes for acute promyelocytic leukemia (APL), although a subset of patients still suffer relapse. The purpose of this study was to evaluate the role of maintenance ... [Published Journal of Clinical Oncology - Sep 23 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Updated Summary: ACR Appropriateness Criteria® rib fractures. [American College of Radiology]

ACR Appropriateness Criteria®Clinical Condition : Rib FractureVariant 1 : Adult. Suspected rib fractures from minor blunt trauma (injury confined to ribs).Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" fie ... [Published National Guideline Clearinghouse - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced...

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced Hematologic MalignanciesBy a News Reporter-Staff News Editor at Clinical Trials Week Boston Strategics Corporation ... [Published Pharmacy Choice - Sep 15 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced...

Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced Hematologic MalignanciesBy a News Reporter-Staff News Editor at Clinical Trials Week -- Boston Strategics Corporation ... [Published 4 Traders - Sep 10 2014]
First reported Sep 06 2014 - Updated Sep 06 2014 - 1 reports

Incidence and risk factors of infectious...

“The purpose of this study was to determine the incidence and risk factors of infections associated with implantable venous access ports (IVAPs).” Shim et al (2014).Reference:Shim, J., Seo, T.S., Song, M.G., Cha, I.H., Kim, J.S., Choi, C.W., Seo, J.H. ... [Published IVTEAM - Sep 06 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Boston Strategics Commences Phase 1 Clinical Trial of Anti-cancer Agent for Fujifilm

Boston Strategics Corp. (BSC) reported that it has begun a Phase 1 clinical trial of Fujifilm's anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic ... [Published Individual.com - Sep 04 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Factors in Late Hospice Admission for Cancer Identified

Share this article:Late admission more likely for younger patients, married men, hematologic malignancies.For patients with cancer , factors associated with late admission to hospice have been identified, according to a study published online in the Journal ... [Published Chemotherapy Advisor - Aug 29 2014]
Entities: Hospice, Cancer, Admission
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ... [Published Marketwire - Breaking News Releases - Jun 12 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Variants of humanized immunomodulatory monoclonal antibodies

The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the ... [Published PharmCast - Apr 15 2014]

Quotes

...Guillermo Garcia-Manero. "This drug will provide another alternative for patients who have failed conventional chemotherapeutic approaches, and we are pleased to be furthering this research at our institution." This clinical trial is the first example of a BSC and FPHU collaboration, whereby BSC optimizes and executes the global strategy of FPHU Oncology drug...
"Quality measures of hospice lengths of stay should include patient-mix adjustments for type of cancer and site of care" the authors write
More From BioPortfolio on "ImmunoGen Inc. Announces Favorable Initial Safety and Response Findings for CD38-Targeting Anticancer Compound, SAR650984"

More Content

All (13) | News (12) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Utility of Routine Post-Therapy Surveillance Im... [Published Journal of Clinical Oncology - 5 hours ago]
Anchors Away [Published Springer Link Journal - Sep 26 2014]
Prevalence, Management, and Clinical Consequenc... [Published Journal of Clinical Oncology - Sep 23 2014]
Tamibarotene As Maintenance Therapy for Acute P... [Published Journal of Clinical Oncology - Sep 23 2014]
Updated Summary: ACR Appropriateness Criteria® ... [Published National Guideline Clearinghouse - Sep 15 2014]
Boston Strategics Corporation Initiates a Phase... [Published Pharmacy Choice - Sep 15 2014]
Boston Strategics Corporation Initiates a Phase... [Published 4 Traders - Sep 10 2014]
Incidence and risk factors of infectious... [Published IVTEAM - Sep 06 2014]
Boston Strategics Commences Phase 1 Clinical Tr... [Published Individual.com - Sep 04 2014]
Factors in Late Hospice Admission for Cancer Id... [Published Chemotherapy Advisor - Aug 29 2014]
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ImmunoGen Inc. Announces Favorable Initial Safe... [Published BioPortfolio - Dec 09 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.